Cargando…
Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Medically At-Risk Children in Australia: A Record Linkage Study
BACKGROUND: Children with chronic medical conditions are at higher risk of invasive pneumococcal disease (IPD), but little is known about the effectiveness of the primary course of pneumococcal conjugate vaccine (PCV) in these children. METHODS: A cohort born in 2001–2004 from two Australian states...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520284/ https://www.ncbi.nlm.nih.gov/pubmed/35640283 http://dx.doi.org/10.1093/jpids/piac038 |
_version_ | 1784799588812587008 |
---|---|
author | Kabir, Alamgir Newall, Anthony T Randall, Deborah Moore, Hannah C Jayasinghe, Sanjay Fathima, Parveen Liu, Bette McIntyre, Peter Gidding, Heather F |
author_facet | Kabir, Alamgir Newall, Anthony T Randall, Deborah Moore, Hannah C Jayasinghe, Sanjay Fathima, Parveen Liu, Bette McIntyre, Peter Gidding, Heather F |
author_sort | Kabir, Alamgir |
collection | PubMed |
description | BACKGROUND: Children with chronic medical conditions are at higher risk of invasive pneumococcal disease (IPD), but little is known about the effectiveness of the primary course of pneumococcal conjugate vaccine (PCV) in these children. METHODS: A cohort born in 2001–2004 from two Australian states and identified as medically at-risk (MAR) of IPD either using ICD-coded hospitalizations (with conditions of interest identified by 6 months of age) or linked perinatal data (for prematurity) were followed to age 5 years for notified IPD by serotype. We categorized fully vaccinated children as either receiving PCV dose 3 by <12 months of age or ≥1 PCV dose at ≥12 months of age. Cox proportional hazard modeling was used to estimate hazard ratios (HRs), adjusted for confounders, and vaccine effectiveness (VE) was estimated as (1-HR) × 100. RESULTS: A total of 9220 children with MAR conditions had 53 episodes of IPD (43 vaccine-type); 4457 (48.3%) were unvaccinated and 4246 (46.1%) were fully vaccinated, with 1371 (32.3%) receiving dose 3 by 12 months and 2875 (67.7%) having ≥1 dose at ≥12 months. Estimated VE in fully vaccinated children was 85.9% (95% CI: 33.9–97.0) against vaccine-type IPD and 71.5% (95% CI: 26.6–88.9) against all-cause IPD. CONCLUSION: This is the first population-based study evaluating the effectiveness of PCV in children with MAR conditions using record linkage. Our study provides evidence that the VE for vaccine-type and all-cause IPD in MAR children in Australia is high and not statistically different from previously reported estimates for the general population. This method can be replicated in other countries to evaluate VE in MAR children. |
format | Online Article Text |
id | pubmed-9520284 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95202842022-10-03 Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Medically At-Risk Children in Australia: A Record Linkage Study Kabir, Alamgir Newall, Anthony T Randall, Deborah Moore, Hannah C Jayasinghe, Sanjay Fathima, Parveen Liu, Bette McIntyre, Peter Gidding, Heather F J Pediatric Infect Dis Soc Original Article BACKGROUND: Children with chronic medical conditions are at higher risk of invasive pneumococcal disease (IPD), but little is known about the effectiveness of the primary course of pneumococcal conjugate vaccine (PCV) in these children. METHODS: A cohort born in 2001–2004 from two Australian states and identified as medically at-risk (MAR) of IPD either using ICD-coded hospitalizations (with conditions of interest identified by 6 months of age) or linked perinatal data (for prematurity) were followed to age 5 years for notified IPD by serotype. We categorized fully vaccinated children as either receiving PCV dose 3 by <12 months of age or ≥1 PCV dose at ≥12 months of age. Cox proportional hazard modeling was used to estimate hazard ratios (HRs), adjusted for confounders, and vaccine effectiveness (VE) was estimated as (1-HR) × 100. RESULTS: A total of 9220 children with MAR conditions had 53 episodes of IPD (43 vaccine-type); 4457 (48.3%) were unvaccinated and 4246 (46.1%) were fully vaccinated, with 1371 (32.3%) receiving dose 3 by 12 months and 2875 (67.7%) having ≥1 dose at ≥12 months. Estimated VE in fully vaccinated children was 85.9% (95% CI: 33.9–97.0) against vaccine-type IPD and 71.5% (95% CI: 26.6–88.9) against all-cause IPD. CONCLUSION: This is the first population-based study evaluating the effectiveness of PCV in children with MAR conditions using record linkage. Our study provides evidence that the VE for vaccine-type and all-cause IPD in MAR children in Australia is high and not statistically different from previously reported estimates for the general population. This method can be replicated in other countries to evaluate VE in MAR children. Oxford University Press 2022-05-30 /pmc/articles/PMC9520284/ /pubmed/35640283 http://dx.doi.org/10.1093/jpids/piac038 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Article Kabir, Alamgir Newall, Anthony T Randall, Deborah Moore, Hannah C Jayasinghe, Sanjay Fathima, Parveen Liu, Bette McIntyre, Peter Gidding, Heather F Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Medically At-Risk Children in Australia: A Record Linkage Study |
title | Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Medically At-Risk Children in Australia: A Record Linkage Study |
title_full | Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Medically At-Risk Children in Australia: A Record Linkage Study |
title_fullStr | Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Medically At-Risk Children in Australia: A Record Linkage Study |
title_full_unstemmed | Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Medically At-Risk Children in Australia: A Record Linkage Study |
title_short | Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Medically At-Risk Children in Australia: A Record Linkage Study |
title_sort | effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in medically at-risk children in australia: a record linkage study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520284/ https://www.ncbi.nlm.nih.gov/pubmed/35640283 http://dx.doi.org/10.1093/jpids/piac038 |
work_keys_str_mv | AT kabiralamgir effectivenessof7valentpneumococcalconjugatevaccineagainstinvasivepneumococcaldiseaseinmedicallyatriskchildreninaustraliaarecordlinkagestudy AT newallanthonyt effectivenessof7valentpneumococcalconjugatevaccineagainstinvasivepneumococcaldiseaseinmedicallyatriskchildreninaustraliaarecordlinkagestudy AT randalldeborah effectivenessof7valentpneumococcalconjugatevaccineagainstinvasivepneumococcaldiseaseinmedicallyatriskchildreninaustraliaarecordlinkagestudy AT moorehannahc effectivenessof7valentpneumococcalconjugatevaccineagainstinvasivepneumococcaldiseaseinmedicallyatriskchildreninaustraliaarecordlinkagestudy AT jayasinghesanjay effectivenessof7valentpneumococcalconjugatevaccineagainstinvasivepneumococcaldiseaseinmedicallyatriskchildreninaustraliaarecordlinkagestudy AT fathimaparveen effectivenessof7valentpneumococcalconjugatevaccineagainstinvasivepneumococcaldiseaseinmedicallyatriskchildreninaustraliaarecordlinkagestudy AT liubette effectivenessof7valentpneumococcalconjugatevaccineagainstinvasivepneumococcaldiseaseinmedicallyatriskchildreninaustraliaarecordlinkagestudy AT mcintyrepeter effectivenessof7valentpneumococcalconjugatevaccineagainstinvasivepneumococcaldiseaseinmedicallyatriskchildreninaustraliaarecordlinkagestudy AT giddingheatherf effectivenessof7valentpneumococcalconjugatevaccineagainstinvasivepneumococcaldiseaseinmedicallyatriskchildreninaustraliaarecordlinkagestudy |